Electroacupuncture therapy improves cognitive dysfunction after ischemic stroke in Sprague-Dawley rats by adjusting the lncRNA-MEG3/miR-4640-3p axis.

电针疗法通过调节 lncRNA-MEG3/miR-4640-3p 轴改善 Sprague-Dawley 大鼠缺血性中风后的认知功能障碍

阅读:13
作者:Zhang Yun, Gao Shiqing, Lin Ling, Zheng Yongbing
BACKGROUND: Ischemic stroke (IS) is a common disease that can cause cognitive dysfunction. Electroacupuncture (EA) is an effective way to alleviate cognitive dysfunction, but its molecular regulatory mechanism is still unclear. Long noncoding RNA-MEG3 (MEG3) is an important factor in the incidence and progression of IS. Herein, we explored the mechanism of EA in IS. METHODS: A middle cerebral artery occlusion (MCAO) model was established in Sprague-Dawley rats to simulate IS in vivo, followed by electroacupuncture (EA) therapy. AAV-control and AAV-MEG3 were injected into the lateral ventricle of rats. All rats except for the sham group underwent MCAO. EA was performed at Shenting and Baihui points for 30 min, once a day for 14 days. The MEG3 and miR-4640-3p levels in brains were measured by qRT-PCR. Dual-luciferase reporter analysis validated the relationship between MEG3 and miR-4640-3p. The Morris water maze test and the neurological function test were carried out. The pathological morphology of the brain tissue was evaluated by H&E staining. Apoptotic cells in brains were examined utilizing TUNEL staining. The contents of Bax, Bcl-2, caspase-3, and CytC were assessed by western blot. RESULTS: EA treatment reduced the content of MEG3 but enhanced miR-4640-3p levels in MCAO rats. MEG3 was a sponge for miR-4640-3p. EA treatment alleviated cognitive dysfunction in MCAO rats by inhibiting MEG3. EA treatment reduced MCAO-induced neural damage and apoptosis by inhibiting MEG3. CONCLUSION: EA improved cognitive dysfunction in IS rats by adjusting the MEG3/miR-4640-3p axis, suggesting that EA may be an effective potential therapeutic strategy for improvement of cognitive dysfunction in IS. This study provided a more reliable experimental basis for clinical EA treatment of IS patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。